ClinicalTrials.Veeva

Menu

Evaluation of a Narrative Communication Intervention to Increase Human Papillomavirus Vaccination Intentions and Uptake

S

Sara Fleszar

Status

Unknown

Conditions

Behavior
Human Papilloma Virus
Intention

Treatments

Behavioral: Common Sense Model Guided Narrative Video

Study type

Interventional

Funder types

Other

Identifiers

NCT05352308
UCM2021-142

Details and patient eligibility

About

The current study aims to evaluate a newly developed CSM narrative intervention in increasing HPV vaccination intentions and uptake in adults aged 18 to 26 years. The efficacy of the newly designed CSM-guided narrative video will be compared against a time and attention video and the standard of care print educational materials in increasing the intentions and uptake of the HPV vaccine in an adult Hispanic-majority college population. It is expected that participants receiving the CSM-guided narrative video will have greater HPV vaccine intentions compared with participants in the time and attention video and standard of care print education material groups. It is also hypothesized that participants receiving the CSM-guided narrative video will have greater HPV vaccine uptake at one month post-intervention compared with participants in the time and attention video and standard of care print education material groups.

Full description

The current study aims to evaluate a newly developed CSM narrative intervention in increasing HPV vaccination intentions and uptake in adults aged 18 to 26 years. The efficacy of the newly designed CSM-guided narrative video will be compared against a time and attention video and the standard of care print educational materials in increasing the intentions and uptake of the HPV vaccine in an adult Hispanic-majority college population.

Main Hypotheses:

H1. Participants receiving the CSM-guided narrative video will have greater HPV vaccine intentions compared with participants in the time and attention video and standard of care print education material groups.

H2. Participants receiving the CSM-guided narrative video will have greater HPV vaccine uptake at one month post-intervention compared with participants in the time and attention video and standard of care print education material groups.

Secondary Hypotheses:

H3: For participants receiving the CSM-guided narrative video compared with participants in the time and attention video and standard of care print education material, it is expected that there will be increases in illness risk perceptions, risk-action coherence, knowledge of the HPV and HPV vaccine, perceived effectiveness of the HPV vaccine, perceived severity and susceptibility of HPV and decreases in perceived harms of the HPV vaccine, barriers to the HPV vaccine, and uncertainty of the HPV vaccine immediately post-intervention as well as one month post-intervention.

H4. It is expected that the relationship between intervention groups (i.e., CSM-guided narrative video, time and attention video, standard of care print material) and vaccine uptake will be moderated by three sets of moderators: (1) knowledge of HPV and the HPV vaccine, illness risk perceptions, risk-action coherence, narrative engagement, and realism, (2) perceived effectiveness of the HPV vaccine, perceived severity and susceptibility of the HPV virus, and perceived harms of the vaccine, barriers to receiving the vaccine, and uncertainty of the vaccine, and (3) vaccine intentions.

H5. It is expected that permissive sexual behavior will moderate the relationship between the intervention groups (i.e., CSM-guided narrative video, time and attention video, standard of care print material) and vaccine intentions and uptake, and knowledge of HPV and the vaccine. Further, it is expected that this relationship will be moderated by religious commitment.

H6. It is expected that there will be a moderating effect of story-telling cultures (Hispanic/Latinx and/or African American/Black compared to non-Hispanic white participants) on the relationship between the intervention groups (i.e., CSM-guided narrative video, time and attention video, standard of care print material) and vaccine intentions and uptake, narrative engagement, and realism.

Participants will be recruited via the University's SONA system for course credits. Students aged 18-26 years who have not received any doses of the HPV vaccine are eligible to participate. After completing the study screener, eligible participants will be directed to Qualtrics, a web-based survey platform. Participants will be asked to provide informed consent and complete a baseline survey. Once the baseline survey is complete, participants will be contacted 2 days post-baseline survey completion. At two days post-baseline participants will be randomized via Qualtrics' Randomizer into either the CSM-guided narrative video, to a time and attention video (i.e., CDC video on binge drinking), or the standard of care print educational materials (i.e., Centers for Disease Control and Prevention's Vaccine Information Statement). Participants will then be directed to a post-intervention survey via Qualtrics. Participants in all groups will be asked to be contacted by the research team one-month post-intervention to assess if they received the HPV vaccine. If they have not received the HPV vaccine, their intentions to receive the vaccine will be assessed as well as the longer-term effects of the groups on illness risk representations, risk-action link coherence, knowledge of HPV and HPV vaccine, and effectiveness, harms, barriers, and uncertainty of the HPV vaccine.

Enrollment

300 estimated patients

Sex

All

Ages

18 to 26 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Undergraduate students enrolled in the university's SONA system
  • Aged 18-26 years
  • Have not received any doses of the HPV vaccine
  • Have working audio (e.g., headphones/speakers)

Exclusion criteria

  • Students who are not undergraduates
  • Undergraduates not participating in the university's SONA system
  • Aged <18 or >26 years
  • Have received any dose/shot (1st, 2nd, or 3rd doses/shots) of the HPV vaccine
  • Do not have working audio (e.g., headphones/speakers)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

300 participants in 3 patient groups

Common Sense Model Guided Narrative Video Group
Experimental group
Description:
The narrative videos is guided by the CSM and designed to provide a comprehensive resource for college students. The narrative video addresses illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers. The format of the narrative video includes (1) a direct testimonial of a college woman (in her dorm room) telling a story to her roommates about what motivated her to get vaccinated, and (2) a conversation among the roommates where information about the HPV vaccine is discussed.
Treatment:
Behavioral: Common Sense Model Guided Narrative Video
Standard of Care Group
No Intervention group
Description:
Participants in the standard of care group will receive the Centers for Disease Control and Prevention's Vaccine Information Statement (VIS; https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf). The VIS contains information about HPV, the HPV vaccine, and the benefits and risks of the vaccine. The VIS will be utilized because healthcare providers are required to distribute the VIS to patients before receiving each dose of the HPV vaccine, it is easy to understand, and it is publicly available information.
Time & Attention Group
No Intervention group
Description:
Participants in the time and attention video group will receive a Centers for Disease Control and Prevention video on binge drinking (https://youtu.be/I9hdkDTaQWU; 4:22 minutes). The video contains information on the health risks of binge drinking including unintended pregnancy, sexually transmitted diseases, injury, car accidents, violence, and HIV/AIDS

Trial contacts and locations

0

Loading...

Central trial contact

Sara Fleszar-Pavlovic; Linda Cameron, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems